Shares of Smith & Nephew plc (LON:SN) have been assigned a consensus rating of “Hold” from the ten research firms that are covering the firm, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is GBX 1,540.63 ($20.13).

A number of equities analysts recently weighed in on the stock. UBS Group reaffirmed a “neutral” rating and set a GBX 1,455 ($19.01) price objective on shares of Smith & Nephew in a research report on Thursday, May 2nd. JPMorgan Chase & Co. increased their price objective on shares of Smith & Nephew from GBX 1,689 ($22.07) to GBX 1,758 ($22.97) and gave the stock a “neutral” rating in a research report on Thursday, May 9th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Smith & Nephew in a research report on Thursday, April 25th. Goldman Sachs Group increased their price objective on shares of Smith & Nephew from GBX 1,400 ($18.29) to GBX 1,440 ($18.82) and gave the stock a “neutral” rating in a research report on Monday, February 11th. Finally, Berenberg Bank reaffirmed a “hold” rating and set a GBX 1,475 ($19.27) price objective on shares of Smith & Nephew in a research report on Friday, April 26th.

In other Smith & Nephew news, insider Roland Diggelmann purchased 1,540 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was bought at an average price of GBX 1,532 ($20.02) per share, with a total value of £23,592.80 ($30,828.17). Also, insider Susan Swabey sold 1,097 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of GBX 1,453 ($18.99), for a total transaction of £15,939.41 ($20,827.66).

Smith & Nephew stock opened at GBX 1,655.50 ($21.63) on Monday. Smith & Nephew has a 1-year low of GBX 1,242.50 ($16.24) and a 1-year high of GBX 1,633.50 ($21.34). The company has a debt-to-equity ratio of 30.12, a current ratio of 2.10 and a quick ratio of 1.08. The company has a market capitalization of $14.46 billion and a PE ratio of 21.87.

Smith & Nephew Company Profile

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

See Also: What is the balance sheet?

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.